The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists.

Autor: Rasmussen VG; Department of Cardiology, Aarhus University Hospital, Skejby, Denmark. vibeke.guldbrand@ki.au.dk, Østergaard K, Dupont E, Poulsen SH
Jazyk: angličtina
Zdroj: Movement disorders : official journal of the Movement Disorder Society [Mov Disord] 2011 Apr; Vol. 26 (5), pp. 801-6.
DOI: 10.1002/mds.23470
Abstrakt: Objectives: Several observational studies suggest an association between treatment with ergoline-derived dopamine agonists and valvular regurgitation. In this article, we present an overview of the literature and conduct a meta-analysis.
Methods: Observational studies addressing the frequency of moderate or severe valvular regurgitation among ergoline-treated patients with Parkinson's disease were considered for a meta-analysis. Pooled risk estimates and the risk of increased pulmonary artery pressure were calculated.
Results: The pooling of data from well-designed observational studies documented that both pergolide (RR = 3.05 [1.71-5.44]) and cabergoline (RR = 6.38 [3.17-12.81]) represent a substantially increased risk of developing moderate to severe valvular regurgitation. In addition, pergolide, but not cabergoline, was associated with an increase in pulmonary artery pressure.
Conclusions: The present meta-analysis confirmed a statistically significant association between pergolide and cabergoline treatment and the risk of moderate to severe valvular regurgitation. An association between bromocriptine and valvular regurgitation cannot be entirely ruled out.
Databáze: MEDLINE
Externí odkaz: